HeartBeam, Inc. Overview
Pro stress-test →HeartBeam is a medical technology company developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. The platform is designed for portable devices for patient use anywhere, enabling physicians to identify cardiac health trends outside traditional medical facilities.
Strategic Profile
Pro stress-test →The company achieved FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software in December 2025. HeartBeam ranked #2 worldwide in 12-lead ECG innovation among 243 companies analyzed, second only to GE HealthCare. The company holds over 20 issued patents related to technology enablement.
Competitive Landscape
Pro stress-test →HeartBeam operates in the ambulatory electrocardiogram solutions market for cardiac disease detection. The company faces competition from established medtech players offering traditional ECG monitoring (GE HealthCare, Philips) and emerging digital health competitors in remote cardiac monitoring. HeartBeam's differentiation lies in its proprietary 3D ECG technology and ability to generate clinical-grade 12-lead output from cable-free portable devices.
Industry Context
HeartBeam, Inc. operates in Medical Device Manufacturing - Cardiac Diagnostics.
Key facts
Founded: 2015 · Headquarters: Santa Clara, California · Employees: 16-26 · Revenue: $750K · Market cap: $94.4M